INTRODUCTION
============

Since Capsule endoscopy (CE) was introduced in 2000, it has been widely used as the main tool for diagnosing small bowel diseases \[[@b1-kjim-2019-312]\]. Although CE is useful for diagnosing small bowel diseases, it has some limitations including incomplete examinations and capsule retention \[[@b2-kjim-2019-312]-[@b4-kjim-2019-312]\]. Occasionally, capsules cannot reach the cecum due to various causes, thus leading to incomplete examination of the small bowel. Another problem is capsule retention. Most patients in whom capsule retention occurs are asymptomatic; however, some require surgical or enteroscopic capsule removal \[[@b4-kjim-2019-312]-[@b9-kjim-2019-312]\]. The clinical performance and complications of small bowel CE include completion rate, capsule retention rate, and indications \[[@b2-kjim-2019-312],[@b3-kjim-2019-312]\]; these have also been described in Korea \[[@b10-kjim-2019-312]\]. This study aimed to investigate the clinical performance and complications of small bowel CE based on 17-year data from a Korean Capsule Endoscopy Registry. Furthermore, recent changes in the clinical performance and complications of small bowel CE were also evaluated.

METHODS
=======

CE registry data from 35 hospitals, collected between October 2002 and April 2019, were retrospectively analyzed. Clinical information, including demographic data, completion rate, capsule retention rate, indications, CE diagnosis, and bowel preparation data, was collected and analyzed. From September 2014, health insurance benefits were provided to patients with obscure gastrointestinal bleeding (OGIB) in Korea. However, for patients with small bowel tumor(s), Crohn's disease, and other small bowel diseases, a patient burden of 80% was applied. As such, data from the most recent 5 years (September 2014 to April 2019) were compared with those from the previous 12 years (October 2002 to August 2014).

Indications for CE included OGIB, abdominal pain, chronic diarrhea, small bowel tumor(s), Crohn's disease, weight loss, protein-losing enteropathy, and screening. OGIB was defined as bleeding of unknown cause that persisted or recurred after initial upper gastrointestinal endoscopy and colonoscopy with negative results \[[@b11-kjim-2019-312],[@b12-kjim-2019-312]\]. In addition to overt bleeding (melena or hematochezia), occult bleeding (persistent iron deficiency anemia or positive stool occult blood) was also considered OGIB \[[@b12-kjim-2019-312],[@b13-kjim-2019-312]\].

Before CE examinations, patients were offered a bowel preparation regimen according to clinician preferences. Options for the bowel preparation included nil per os (NPO), polyethylene glycol (PEG), PEG + ascorbic acid, sodium phosphate (NaP), picosulfate, or others. Bowel preparation quality was categorized by independent examiners as follows: excellent, ≥ 75% of the mucosa visualized; good, 50% to 74% of the mucosa visualized; fair, 25% to 49% of the mucosa visualized; poor, ≤ 24% of the mucosa visualized \[[@b14-kjim-2019-312]\]. For the purpose of study analysis, excellent or good bowel preparation were deemed adequate, and fair or poor preparation were deemed inadequate \[[@b15-kjim-2019-312]\]. Comparison was performed between adequate and inadequate bowel preparation quality.

CE diagnoses were based on CE structured terminology. Complete examination was defined when the capsule reached the cecum during the recording time \[[@b2-kjim-2019-312],[@b3-kjim-2019-312]\]. Capsule retention was defined when the capsule remained in the digestive tract for \> 2 weeks \[[@b2-kjim-2019-312],[@b10-kjim-2019-312]\]. Completion and capsule retention rates were calculated, and risk factors affecting incomplete examination and capsule retention were also investigated. Acquisition of informed consent was exempted and the study design was approved by the Institutional Review Board of Seoul Metropolitan Government Seoul National University Boramae Medical Center (approval number: 20190802/10-2019-62/091).

Data are expressed as mean ± standard deviation (SD) for continuous variables and number (%) for categorical variables. Risk factors for incomplete examination and capsule retention were analyzed using logistic regression models. Statistical analysis was performed using SPSS version 20.0 (IBM Corporation, Armonk, NY, USA).

RESULTS
=======

Demographics and indications
----------------------------

A total of 4,650 CE examinations were analyzed. The mean ± SD age of the study population was 53.5 ± 18.8 years, and 60.3% was male. The overall incomplete examination rate was 16.3%, and the capsule retention rate was 3%. The incomplete examination rate of recent CE examinations (from September 2014 to April 2019) decreased compared with that of previous examinations (9.4% vs. 18.9%, *p* \< 0.001) ([Table 1](#t1-kjim-2019-312){ref-type="table"}). The most common indication for CE was OGIB (64.4%). Patients in whom the indication for CE was OGIB accounted for 68.8% in recent CE examinations and 62.7% in previous CE examinations (*p* \< 0.001) ([Table 2](#t2-kjim-2019-312){ref-type="table"}).

CE diagnoses
------------

Positive CE diagnosis was obtained in 63.8% CE examinations, while negative (normal) CE diagnosis was obtained in 36.2% CE examinations. Recent CE examinations yielded normal results in 28.4%, which was lower than the normal results in previous CE examinations (38.5%) (*p* \< 0.001). CE diagnoses are summarized in [Table 3](#t3-kjim-2019-312){ref-type="table"}. A recent increasing trend of CE diagnosis of Crohn's disease was observed (6.3% vs. 8.5%, *p* = 0.014). Regarding nonsteroidal anti-inflammatory drug (NSAID) enteropathy, significant changes with time were not observed (5.7% vs. 6.5%, *p* = 0.305).

Factors associated with incomplete examination and capsule retention
--------------------------------------------------------------------

Factors associated with incomplete examination included inadequate bowel preparation and an indication other than OGIB ([Table 4](#t4-kjim-2019-312){ref-type="table"}). Crohn's disease was a risk factor for capsule retention, and inadequate bowel preparation was significantly associated with capsule retention ([Table 5](#t5-kjim-2019-312){ref-type="table"}). The capsule retention rate was the highest among patients with Crohn's disease ([Table 6](#t6-kjim-2019-312){ref-type="table"}).

Bowel preparation
-----------------

The quality of bowel preparation significantly differed according to bowel preparation regimen ([Table 7](#t7-kjim-2019-312){ref-type="table"}). When the proportion of adequate bowel preparation after ingesting the bowel preparation regimen was compared pairwise with that after NPO, significant differences were identified for PEG 4 L, PEG + ascorbic acid 2 L, and NaP (*p* = 0.017, *p* \< 0.001, *p* = 0.028, respectively). When Bonferroni correction was applied for multiple comparisons (*p* \< 0.0125), the proportion of adequate bowel preparation was different only between PEG + ascorbic acid 2 L and NPO. PEG 2 L was previously the most commonly used regimen (47.9%); however, recently, the PEG + ascorbic acid regimen has become the most popular (58.1%) ([Table 8](#t8-kjim-2019-312){ref-type="table"}).

DISCUSSION
==========

In this registry-based study including 4,650 CE examinations, the incomplete examination and capsule retention rates were determined. This study revealed an incomplete examination rate of 16%, which is similar to that reported in previous studies \[[@b2-kjim-2019-312],[@b3-kjim-2019-312]\]. The capsule retention rate was 3%, which is slightly higher than that reported in previous studies \[[@b2-kjim-2019-312],[@b3-kjim-2019-312]\]. The incomplete examination rate of recent CE (September 2014 to April 2019) decreased compared with that of previous CE (October 2002 to August 2014). With the extended battery life of newer CE technologies, more capsules have reached the ileocecal valve and cecum, leading to a decrease in the number of incomplete examinations \[[@b16-kjim-2019-312],[@b17-kjim-2019-312]\]. With technical advances in radiological examinations, such as computed tomography enterography and magnetic resonance enterography, more patients with small bowel stricture(s) can be diagnosed before undergoing CE. However, the decrease in capsule retention rate over time was not statistically significant in our study. Moreover, our data lacked radiological examination results and, thus, analysis in this regard was not possible. The most common indication for CE was OGIB (64.4%), which is consistent with results reported in previous studies \[[@b2-kjim-2019-312],[@b3-kjim-2019-312],[@b10-kjim-2019-312]\]. In our study, recent CE examinations had more OGIB indications than previous CE examinations (*p* \< 0.001), which can be explained by the inception of health insurance coverage for patients with OGIB in September 2014.

Recently, the incidence of Crohn's disease has been found to be increasing in Korea \[[@b18-kjim-2019-312]\]. Our study revealed a recent increasing tendency of indications and CE diagnosis of Crohn's disease. CE diagnosis of NSAID enteropathy demonstrated an increasing tendency without statistical significance. The increase in NSAID enteropathy can be attributed to the aging population. In our study, the proportion of normal results was smaller in recent CE examinations than in previous examinations. Recent advances in CE technology with improved resolution may have led to more lesion detection and fewer patients diagnosed with normal findings.

Our study revealed that factors associated with incomplete examination were inadequate bowel preparation and indications other than OGIB, which is consistent with the results of a previous study \[[@b10-kjim-2019-312]\]. With adequate bowel preparation, CE is more likely to be completed. Blood materials in patients with gastrointestinal bleeding appear to act as laxatives, thus helping the capsule proceed through the ileocecal valve. In our study, inadequate bowel preparation was significantly associated with capsule retention, which is also consistent with the results of previous studies \[[@b2-kjim-2019-312],[@b10-kjim-2019-312]\]. The presence of stenotic portions in the small bowel may lead to both inadequate bowel preparation and capsule retention. Additionally, fecal materials stuck in the stenotic portion may result in capsule retention. Although causality was difficult to determine, our study revealed that inadequate bowel preparation was significantly associated with capsule retention. Crohn's disease was a risk factor for capsule retention and the capsule retention rate was the highest among patients with the indication of Crohn's disease. Special caution or using a patency capsule will be needed in patients with Crohn's disease.

In this study, bowel preparation quality was affected by the bowel preparation regimen. PEG 4 L or NaP more favorably affected bowel preparation than NPO; however, PEG + ascorbic acid resulted in worse bowel preparation than NPO. In our study, the recent data revealed that PEG + ascorbic acid regimen was the most widely used. This can be explained by the fact that recent guidelines recommend that CE should be performed as soon as possible (generally after colonoscopy) in patients with overt, obscure bleeding \[[@b11-kjim-2019-312]\], and PEG + ascorbic acid has recently become the most popular regimen for colonoscopy in Korea \[[@b19-kjim-2019-312]\]. The time interval from the ingestion of the bowel preparation regimen to performing CE can be delayed because performing colonoscopy and clinician's decision-making to perform CE after colonoscopy can take time. This time delay may adversely affect bowel preparation quality \[[@b20-kjim-2019-312],[@b21-kjim-2019-312]\], because debris and intestinal fluid can affect preparation of the distal small bowel \[[@b22-kjim-2019-312]\].

Our study had some limitations, the first of which was its retrospective design and, as such, may have been susceptible to selection bias. Moreover, our data may have been susceptible to the under-reporting of complications. Second, our investigation was a multi-center, registry-based study, and the data collection methods used at each institution were not monitored. There was no auditing system to control data collection. However, this was a large study based on 17-year registry data. Time trends were also investigated between recent and previous data.

In conclusion, our 17-year data suggest that CE is a useful and safe tool for diagnosing small bowel diseases. The incomplete examination rate of CE decreased with time and OGIB was consistently the primary indication for CE. Inadequate bowel preparation was significantly associated with capsule retention and incomplete examination.

KEY MESSAGE
===========

1\. The incomplete examination rate of capsule endoscopy decreased over time.

2\. Obscure gastrointestinal bleeding was consistently the primary indication for capsule endoscopy.

3\. Inadequate bowel preparation was significantly associated with capsule retention and incomplete examination.
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###### 

Demographic information and incomplete examination and retention rates

  Variable       Total          \~Aug. 31, 2014   Sep. 1, 2014\~
  -------------- -------------- ----------------- ----------------------------------------------------------
  Age            53.5 ± 18.8    53.1 ± 18.1       55.0 ± 20.5
  Male sex       2,804 (60.3)   2,067 (61.1)      681 (58.2)
  Incompletion   678 (16.3)     570 (18.9)        108 (9.4)^[a](#tfn1-kjim-2019-312){ref-type="table-fn"}^
  Retention      125 (3.0)      105 (3.2)         20 (2.6)

Values are presented as mean ± SD or number (%).

Decreased trend.

###### 

Indications for capsule endoscopy

  Variable                         Total          \~Aug. 31, 2014   Sep. 1, 2014\~
  -------------------------------- -------------- ----------------- -----------------------------------------------------------
  Obscure GI bleeding              2,965 (64.4)   2,110 (62.7)      790 (68.8)^[a](#tfn2-kjim-2019-312){ref-type="table-fn"}^
   Overt                           2,445 (53.1)   1,755 (52.2)      638 (55.6)
   Occult                          520 (11.3)     355 (10.5)        152 (13.2)
  Abdominal pain                   724 (15.7)     594 (17.7)        117 (10.2)
  Crohn's disease                  212 (4.6)      119 (3.5)         86 (7.5)^[a](#tfn2-kjim-2019-312){ref-type="table-fn"}^
  Small bowel tumor                166 (3.6)      122 (3.6)         42 (3.7)
  Chronic diarrhea                 171 (3.7)      118 (3.5)         51 (4.4)
  Weight loss                      19 (0.4)       18 (0.5)          1 (0.1)
  Cancer of unknown primary site   4 (0.1)        3 (0.1)           0
  Protein-losing enteropathy       15 (0.3)       6 (0.2)           7 (0.6)
  Behcet's disease, TB enteritis   44 (1.0)       21 (0.6)          23 (2.0)
  Ileus                            13 (0.3)       5 (0.1)           8 (0.7)
  Screening                        214 (4.6)      209 (6.2)         2 (0.2)

Values are presented as number (%).

GI, gastrointestinal; TB, tuberculous.

Increased trend.

###### 

Capsule endoscopic diagnosis

  Variable                                              Total          \~Aug. 31, 2014   Sep. 1, 2014\~
  ----------------------------------------------------- -------------- ----------------- -----------------------------------------------------------
  Normal                                                1,647 (36.2)   1,285 (38.5)      322 (28.4)^[a](#tfn3-kjim-2019-312){ref-type="table-fn"}^
  Vascular lesions                                                                       
   Angiodysplasia, telangiectasia, Dieulafoy's lesion   442 (9.7)      349 (10.4)        87 (7.7)
   Bleeding of unidentified origin                      234 (5.1)      122 (3.7)         109 (9.6)
   Varices                                              12 (0.3)       10 (0.3)          2 (0.2)
  Inflammatory lesions                                                                   
   Erosion, not signified                               365 (8.0)      233 (7)           130 (11.5)
   Ulcer, not signified                                 469 (10.3)     352 (10.5)        112 (9.9)
   Hemorrhagic enteropathy                              31 (0.7)       28 (0.8)          3 (0.3)
   Congestive enteropathy                               13 (0.3)       13 (0.4)          6 (0.5)
   H-S purpura, vasculitis                              11 (0.2)       10 (0.3)          1 (0.1)
   Ischemic enteritis                                   9 (0.2)        6 (0.2)           3 (0.3)
   NSAID enteropathy                                    267 (5.9)      190 (5.7)         74 (6.5)
   TB enteritis                                         30 (0.7)       16 (0.5)          12 (1.1)
   Behcet's enteritis                                   33 (0.7)       22 (0.7)          11 (1.0)
   Radiation enteritis                                  9 (0.2)        8 (0.2)           0
   Eosinophilic enteritis                               18 (0.4)       10 (0.3)          6 (0.5)
   Crohn's disease                                      316 (6.9)      211 (6.3)         96 (8.5)^[b](#tfn4-kjim-2019-312){ref-type="table-fn"}^
   CMUSE                                                3 (0.1)        1 (0)             2 (0.2)
  Tumor lesions                                                                          
   Lymphoid hyperplasia                                 25 (0.5)       22 (0.7)          3 (0.3)
   Lymphangiectasia                                     30 (0.7)       17 (0.5)          12 (1.1)
   Malignant tumor                                      50 (1.1)       40 (1.2)          9 (0.8)
   Submucosal tumor                                     146 (3.2)      120 (3.6)         24 (2.1)
   Polyp, adenomatous                                   25 (0.5)       21 (0.6)          4 (0.4)
   Polyp, non-neoplastic                                134 (2.9)      105 (3.1)         25 (2.2)
   Peutz-Jeghers syndrome                               10 (0.2)       7 (0.2)           3 (0.3)
   Hemangioma                                           4 (0.1)        2 (0.1)           2 (0.2)
   Lymphangioma                                         3 (0.1)        2 (0.1)           1 (0.1)
  Others                                                220 (4.8)      138 (4.1)         82 (7.2)

Values are presented as number (%).

H-S, Henoch--Schönlein; NSAID, nonsteroidal anti-inflammatory drug; TB, tuberculous; CMUSE, cryptogenic multifocal ulcerous stenosing enteritis.

Decreased trend.

Increased trend.

###### 

Factors associated with incomplete examination

  Variable                           Crude   Age and sex adjusted                                     
  ---------------------------------- ------- ---------------------- ---------- ------- -------------- ----------
  Age                                1.005   1.001--1.009           0.026                             
  Male sex                           0.911   0.771--1.076           0.274                             
  Indication for capsule endoscopy                                                                    
   OGIB vs. others                   0.761   0.642--0.902           0.002      0.712   0.597--0.850   \< 0.001
   Crohn's disease vs. others        0.864   0.574--1.301           0.484      0.966   0.636--1.467   0.871
   Small bowel tumor vs. others      0.827   0.523--1.308           0.418      0.868   0.548--1.375   0.548
  Bowel preparation                                                                                   
   Inadequate vs. adequate           1.757   1.479--2.086           \< 0.001   1.750   1.472--2.080   \< 0.001

OR, odds ratio; CI, confidence interval; OGIB, obscure gastrointestinal bleeding.

###### 

Factors associated with capsule retention

  Variable                           Crude   Age and sex adjusted                                     
  ---------------------------------- ------- ---------------------- ---------- ------- -------------- ----------
  Age                                0.999   0.989--1.008           0.814                             
  Male sex                           0.83    0.580--1.188           0.309                             
  Indication for capsule endoscopy                                                                    
   OGIB vs. others                   1.083   0.745--1.575           0.677      1.092   0.743--1.604   0.654
   Crohn's disease vs. others        2.264   1.226--4.182           0.009      2.380   1.258--4.505   0.008
   Small bowel tumor vs. others      0.213   0.030--1.533           0.124      0.209   0.029--1.506   0.120
  Bowel preparation                                                                                   
   Inadequate vs. adequate           2.434   1.677--3.533           \< 0.001   2.412   1.657--3.510   \< 0.001

OR, odds ratio; CI, confidence interval; OGIB, obscure gastrointestinal bleeding.

###### 

Capsule retention rates according to indications for capsule endoscopy

  Indications of capsule endoscopy   No. (%)
  ---------------------------------- ----------
  Obscure GI bleeding                82 (3.1)
  Abdominal pain                     20 (3.0)
  Crohn's disease                    12 (6.3)
  Small bowel tumor                  1 (0.7)
  Screening                          0
  Chronic diarrhea                   2 (1.3)

GI, gastrointestinal.

###### 

Bowel preparation quality according to bowel preparation method

  Variable            NPO          PEG 4 L                                                     PEG 2 L        PEG + Asc 2 L                                               NaP                                                         *p* value
  ------------------- ------------ ----------------------------------------------------------- -------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------
  Quality                                                                                                                                                                                                                             \< 0.001
   Excellent          149 (21.4)   104 (16.1)                                                  165 (10.8)     92 (13.5)                                                   89 (30.3)                                                   
   Good               340 (48.9)   388 (60.1)                                                  874 (57.5)     289 (42.6)                                                  138 (46.9)                                                  
   Fair               161 (23.2)   119 (18.4)                                                  368 (24.2)     215 (31.7)                                                  53 (18.0)                                                   
   Poor               45 (6.5)     35 (5.4)                                                    114 (7.5)      83 (12.2)                                                   14 (4.8)                                                    
  Acceptability                                                                                                                                                                                                                       \< 0.001
   Adequate           489 (70.4)   492^[a](#tfn5-kjim-2019-312){ref-type="table-fn"}^ (76.2)   1,039 (68.3)   381^[a](#tfn5-kjim-2019-312){ref-type="table-fn"}^ (56.1)   227^[a](#tfn5-kjim-2019-312){ref-type="table-fn"}^ (77.2)   
   Inadequate         206 (29.6)   154 (23.8)                                                  482 (31.7)     298 (43.9)                                                  67 (22.8)                                                   
  *p* value vs. NPO   Reference    0.017                                                       0.333          \< 0.001                                                    0.028                                                       

Values are presented as number (%).

NPO, *nil* per os; PEG, polyethylene glycol; Asc, ascorbic acid; NaP, sodium phosphate.

Statistically significant in comparison with NPO (*p* \< 0.05).

###### 

Trends in bowel preparation methods

  Variable        Total          \~Aug. 31, 2014   Sep. 1, 2014\~
  --------------- -------------- ----------------- ----------------
  NPO             704 (17.5)     560 (19.2)        144 (12.9)
  PEG 4 L         658 (16.3)     546 (18.7)        111 (10.0)
  PEG 2 L         1,553 (38.5)   1,398 (47.9)      155 (13.9)
  PEG + Asc 2 L   681 (16.9)     34 (1.2)          646 (58.1)
  NaP             297 (7.4)      297 (10.2)        0
  Picosulfate     64 (1.6)       8 (0.3)           56 (4.8)
  Others          77 (1.9)       77 (2.7)          0

Values are presented as number (%).

NPO, *nil* per os; PEG, polyethylene glycol; Asc, ascorbic acid; NaP, sodium phosphate.
